Press Releases

EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments
May 05, 2021
  - EYP-1901 DAVIO study for the potential treatment of wet AMD dosed first patient in January; study remains on track for initial data in Q4 2021; -Completed $115.1 million follow-on financing in February 2021 ; -Net product revenues of $6.8 million versus $4.7 million in Q1 2020, a 45% increase;
EyePoint Pharmaceuticals to Report First Quarter 2021 Financial Results and Discuss Recent Corporate Developments on May 5, 2021
Apr 28, 2021
WATERTOWN, Mass. , April 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and
EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Corporate Developments
Mar 04, 2021
-   $115.1 million   follow-on financing completed in February 2021 - First patient dosed in Phase 1 clinical trial with EYP-1901 in January 2021 -   $16.5 million monetization of ILUVIEN Royalty with $15 million applied to reduction in debt obligations in December 2020   - $15.7 million equity
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Feb 25, 2021
WATERTOWN, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that management will present at two
EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
Feb 25, 2021
WATERTOWN, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and
EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock
Feb 04, 2021
WATERTOWN, Mass. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of an underwritten
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Feb 01, 2021
WATERTOWN, Mass. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an underwritten
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Feb 01, 2021
WATERTOWN, Mass. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it intends to offer and sell
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
Jan 28, 2021
WATERTOWN, Mass. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the first patient has been
EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues
Jan 11, 2021
- IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal  anti-VEGF treatment targeting wet age-related macular degeneration - - Anticipated Phase 1 clinical trial initiation in Q1 2021 - - Q4 2020 net product revenues are estimated to be $6.2 - $6.6
EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics
Jan 03, 2021
WATERTOWN, Mass. , Jan. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics , a China -based ophthalmic pharmaceutical company
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation
Dec 18, 2020
WATERTOWN, Mass. , Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders, today announced a royalty monetization
EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Dec 08, 2020
WATERTOWN, Mass. , Dec. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it will effect a 1-for-10 reverse stock split at 5:00 p.m.
EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration
Dec 03, 2020
- No unexpected safety findings during the course of the study - -   On track to file an IND by end of year; Phase 1 clinical trial to commence in early 2021 - WATERTOWN, Mass. , Dec. 03, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to
EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4
Nov 19, 2020
WATERTOWN, Mass. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the future of local
EyePoint Pharmaceuticals Presents Positive Data of YUTIQ® and DEXYCU® in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
Nov 16, 2020
-   Second Phase 3 trial of YUTIQ   confirms 36-month   positive efficacy   results from the first Phase 3 trial - -   Study of DEXYCU vs. Prednisolone e ye d rops shows high patient preference for D EXYCU regimen with statistically better inflammation control, pain, visual acuity outcomes in D
EyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting
Nov 10, 2020
WATERTOWN, Mass. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that four abstracts featuring YUTIQ® and DEXYCU® have been selected for
EyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments
Nov 05, 2020
- Total revenues of $ 15.7 million and net product revenues of $ 5. 8 million - -   S equential quarterly increase in underlying customer demand of   over 12 0 % for DEXYCU ® and over 5% for YUTIQ®   - - EYP-1901, a potential six-month sustained delivery   intravitreal anti-VEGF treatment targeting
EyePoint Pharmaceuticals Announces Third Quarter 2020 Financial Results Release Date and Conference Call Information
Oct 29, 2020
WATERTOWN, Mass. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter 2020 on Thursday, November 5, 2020 .
EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants
Oct 08, 2020
WATERTOWN, Mass. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced an amendment to its existing debt facility with CRG Servicing LLC (CRG).
Displaying 61 - 80 of 465